| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/06/2014 | US20140037578 IL-25 Treatment of Obesity and Metabolic Disorders |
| 02/06/2014 | US20140037554 Cupredoxin derived transport agents and methods of use thereof |
| 02/06/2014 | US20140037551 Antibodies to human b7x for treatment of metastatic cancer |
| 02/06/2014 | US20140037547 NOVEL PEPTIDIC ACTIVATORS OF TYPE I cGMP DEPENDENT PROTEIN KINASES AND USES THEREOF |
| 02/06/2014 | US20140037539 Antibody cocktails for breast cancer radioimmunotherapy |
| 02/06/2014 | US20140034873 Buffered compositions for dialysis |
| 02/05/2014 | EP2692359A1 Potentiator of cancer immunity containing rankl antagonist |
| 02/05/2014 | EP2692352A1 Hot flash suppressant |
| 02/05/2014 | EP2691114A1 Delivery of large molecular weight biologically active substances |
| 02/05/2014 | EP2691095A2 Imidazolyl amide compounds and uses related thereto |
| 02/05/2014 | EP2691089A1 Nutritional compositions for increasing arginine levels and methods of using same |
| 02/05/2014 | CN103561775A Liposome containing shRNA molecule for thymidylate synthase, and use for same |
| 02/05/2014 | CN103561769A Pharmaceutical preparation |
| 02/05/2014 | CN103561768A Anti-inflammatory composition |
| 02/05/2014 | CN103561767A Polyphenol composition for preventing or treating atherosclerosis |
| 02/05/2014 | CN103561766A S1P antagonists as adjunct ocular hypotensives |
| 02/05/2014 | CN103561749A Vaginal composition based on alkyl polyglucosides |
| 02/05/2014 | CN103561740A Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's disease |
| 02/05/2014 | CN103561731A Dry powder inhaler compositions comprising umeclidinium |
| 02/05/2014 | CN103550847A Novel formulations for treatment of migraine |
| 02/05/2014 | CN103550778A Pharmaceutical composition for treating affective disorder disease |
| 02/05/2014 | CN103550777A Multi-drug self-aggregation composite nanoparticles as well as preparation method and application thereof |
| 02/05/2014 | CN103550776A Hydrophobic drug nanoparticles as well as preparation method and application thereof |
| 02/05/2014 | CN103550775A Anti-insomnia composition, application of composition, multi-phase pulse immediate-release preparation prepared by use of composition and preparation method of preparation |
| 02/05/2014 | CN103550178A Particulate comprising a calcium-containing compound and a sugar alcohol |
| 02/05/2014 | CN103550150A Improved dimethicone-containing injection |
| 02/05/2014 | CN103550149A Technology for preparing long-acting injection containing antiparasitic drugs |
| 02/05/2014 | CN103550139A Preparation method of injectable self-curing hypoglycemic hydrogel |
| 02/05/2014 | CN103550136A Transmucosal delivery devices with enhanced uptake |
| 02/05/2014 | CN102028947B Inhibitor, inhibitor composition and inhibiting method of FAM3B gene, fatty liver treatment method and pharmaceutical application of inhibitor |
| 02/04/2014 | US8642779 Compositions useful as inhibitors of protein kinases |
| 02/04/2014 | US8642600 Method of treating autism |
| 02/04/2014 | US8642580 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and platinum derivatives |
| 02/04/2014 | US8642291 Method for producing proteins comprising non-natural amino acids incorporated therein |
| 02/04/2014 | US8642051 Method of hydration; infusion packet system(s), support member(s), delivery system(s), and method(s); with business model(s) and Method(s) |
| 02/04/2014 | US8642037 Antibodies to insulin-like growth factor I receptor |
| 02/04/2014 | US8642036 Treatment with anti-ErbB2 antibodies |
| 02/04/2014 | US8642027 Compositions and methods for modulating ischemic injury |
| 02/04/2014 | US8642026 Methods and compositions for contributing to the treatment of cancers |
| 02/04/2014 | CA2697520C Use of lyophilised reduced diaminophenothiazines in the treatment of tau mediated neurological disorders |
| 02/04/2014 | CA2666750C Phenylpropionamide compounds and the use thereof |
| 02/04/2014 | CA2539273C A fusion protein comprising an interleukin-1 receptor antagonist and uses thereof |
| 02/04/2014 | CA2453470C Use of follistatin for the treatment of hepatic fibrogenesis |
| 02/04/2014 | CA2432797C Local regional chemotherapy and radiotherapy using in situ hydrogel |
| 01/30/2014 | WO2014017569A1 Pharmaceutical product for lowering blood ldl |
| 01/30/2014 | WO2014017491A1 Fusion gene of cep55 gene and ret gene |
| 01/30/2014 | WO2014017462A1 Pharmaceutical composition for inhibiting abnormal spine formation |
| 01/30/2014 | WO2014017342A1 Indole derivative or pharmacologically acceptable salt thereof |
| 01/30/2014 | WO2014017319A1 Filaggrin production promoter, therapeutic agent for diseases associated with reduction in production of filaggrin, and method for screening for said therapeutic agent |
| 01/30/2014 | WO2014017046A1 Prophylactic and/or therapeutic agent for radiation damage |
| 01/30/2014 | WO2014016627A1 Vitamin and mineral preparations for gravidae for use in trimesters of pregnancy |
| 01/30/2014 | WO2014016548A2 Pharmaceutical composition |
| 01/30/2014 | WO2014016507A1 Novel selective compounds inhibiting cyp26a1 useful in cosmetic and pharmaceutical compositions |
| 01/30/2014 | WO2014016504A1 System for delivering lectin-based active ingredients |
| 01/30/2014 | US20140031539 6-ether/thioether-purines as topoisomerase ii catalytic inhibitors and their use in therapy |
| 01/30/2014 | US20140031429 Compounds for treating proliferative disorders |
| 01/30/2014 | US20140031404 Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers |
| 01/30/2014 | US20140031400 Macrocyclic compounds and methods of treatment |
| 01/30/2014 | US20140031397 Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient |
| 01/30/2014 | US20140031396 Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient |
| 01/30/2014 | US20140031391 Novel 5-aminotetrahydroquinoline-2-carboxylic acids and their use |
| 01/30/2014 | US20140031379 Camsylate Salt |
| 01/30/2014 | US20140031372 Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome |
| 01/30/2014 | US20140031369 N-cyclopropyl-n-piperidinyl-amide derivatives, pharmaceutical compositions containing them and uses thereof |
| 01/30/2014 | US20140031364 Phenyl-isoxazol derivatives and preparation process thereof |
| 01/30/2014 | US20140031362 Tri - and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent |
| 01/30/2014 | US20140031359 Method Of Treating Metabolic Disorders And Depression With Dopamine Receptor Agonists |
| 01/30/2014 | US20140031349 Inhibitors of the renal outer medullary potassium channel |
| 01/30/2014 | US20140031348 Heteroaryl sulfonamides and ccr2/ccr9 |
| 01/30/2014 | US20140031346 5,6-dihydro-1h-pyridin-2-one compounds |
| 01/30/2014 | US20140031345 Quinazolines as potassium ion channel inhibitors |
| 01/30/2014 | US20140031338 Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| 01/30/2014 | US20140031320 Anti-Thrombotic Compounds |
| 01/30/2014 | US20140031316 Polysaccharides comprising two antithrombin iii-binding sites, preparation thereof and use thereof as antithrombotic medicaments |
| 01/30/2014 | US20140031312 Compositions and formulations of glucosamine for transdermal and transmucosal administration |
| 01/30/2014 | US20140031309 Beta-L-N4 Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases |
| 01/30/2014 | US20140031304 Anti-cholesterolemic compounds and methods of use |
| 01/30/2014 | US20140031290 Novel glp-1 receptor stabilizers and modulators |
| 01/30/2014 | US20140031288 Novel composition for tumor growth control |
| 01/30/2014 | US20140031278 Novel Glucagon Analogues |
| 01/30/2014 | US20140031277 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 01/30/2014 | US20140031276 Compounds and methods for preventing or treating a viral infection |
| 01/30/2014 | US20140030359 Methods and Compositions for Treating Thyroid-Related Medical Conditions with Reduced Folates |
| 01/30/2014 | US20140030356 Method for treating a pulmonary hypertension condition without companion diagnosis |
| 01/30/2014 | US20140030355 Feed composition comprising a mineral complex and methods of using the mineral complex |
| 01/30/2014 | US20140030337 Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye |
| 01/30/2014 | US20140030334 Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes |
| 01/30/2014 | US20140030332 Chemosensory Receptor Ligand-Based Therapies |
| 01/30/2014 | US20140030326 Effervescent formulations comprising dexketoprofen |
| 01/30/2014 | US20140030324 Compositions and methods for treating or preventing oxalate-related disease |
| 01/30/2014 | US20140030323 Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation |
| 01/30/2014 | US20140030319 Antagonists Of The Oncongenic Activity Of The Protein MDM2, And Use Thereof In the Treatment of Cancers |
| 01/30/2014 | US20140030314 Treatment of skin disease |
| 01/30/2014 | US20140030307 New combination comprising n-acetyl-l-cysteine and its use |
| 01/30/2014 | US20140030295 Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response |
| 01/30/2014 | US20140030282 Anti-cd79b antibodies and immunoconjugates |
| 01/30/2014 | US20140030281 Anti-cd22 antibodies and immunoconjugates |
| 01/30/2014 | US20140030280 Anti-cd79b antibodies and immunoconjugates |
| 01/30/2014 | US20140030279 Anti-cd22 antibodies and immunoconjugates |
| 01/30/2014 | US20140030277 Immunomodulating compositions and methods of use thereof |